Pulmonary Fibrosis in a Patient With a Prolactinoma on Dopamine Agonists: Coincidence or Consequence.

JCEM case reports Pub Date : 2025-04-15 eCollection Date: 2025-05-01 DOI:10.1210/jcemcr/luaf067
Ravi Shah, Amanjit Bal, Durairaj Arjunan, Jayaditya Ghosh, Ashley B Grossman, Pinaki Dutta
{"title":"Pulmonary Fibrosis in a Patient With a Prolactinoma on Dopamine Agonists: Coincidence or Consequence.","authors":"Ravi Shah, Amanjit Bal, Durairaj Arjunan, Jayaditya Ghosh, Ashley B Grossman, Pinaki Dutta","doi":"10.1210/jcemcr/luaf067","DOIUrl":null,"url":null,"abstract":"<p><p>Prolactinomas are the most common functional pituitary tumor and are typically managed with dopamine agonists such as bromocriptine or cabergoline. Although these agents are generally well tolerated and effective in reducing prolactin levels and often tumor size, they have been implicated in rare but serious fibrotic complications, including interstitial lung disease (ILD). We describe a 65-year-old man with a longstanding prolactinoma who received cumulative high-dose bromocriptine and cabergoline therapy over several decades. Despite initial tumor shrinkage and partial biochemical control of hyperprolactinemia with dopamine agonists, stereotactic radiosurgery, and transsphenoidal surgery, the patient developed progressive exertional dyspnea and cough, accompanied by imaging and histopathological findings consistent with \"usual interstitial pneumonia\" (UIP). Autoimmune and environmental causes were largely excluded, suggesting a drug-induced etiology. Following discontinuation of cabergoline, the patient has been on continued surveillance of his prolactin levels and tumor status, with symptomatic treatment of his UIP. This case underscores the potential for dopamine agonist-associated ILD, even in patients with prolactinomas who generally receive lower weekly doses than those used in Parkinson's and related diseases. Early recognition of respiratory symptoms, pulmonary function, and radiological investigations are indicated in selected symptomatic cases.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"3 5","pages":"luaf067"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11997647/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCEM case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jcemcr/luaf067","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Prolactinomas are the most common functional pituitary tumor and are typically managed with dopamine agonists such as bromocriptine or cabergoline. Although these agents are generally well tolerated and effective in reducing prolactin levels and often tumor size, they have been implicated in rare but serious fibrotic complications, including interstitial lung disease (ILD). We describe a 65-year-old man with a longstanding prolactinoma who received cumulative high-dose bromocriptine and cabergoline therapy over several decades. Despite initial tumor shrinkage and partial biochemical control of hyperprolactinemia with dopamine agonists, stereotactic radiosurgery, and transsphenoidal surgery, the patient developed progressive exertional dyspnea and cough, accompanied by imaging and histopathological findings consistent with "usual interstitial pneumonia" (UIP). Autoimmune and environmental causes were largely excluded, suggesting a drug-induced etiology. Following discontinuation of cabergoline, the patient has been on continued surveillance of his prolactin levels and tumor status, with symptomatic treatment of his UIP. This case underscores the potential for dopamine agonist-associated ILD, even in patients with prolactinomas who generally receive lower weekly doses than those used in Parkinson's and related diseases. Early recognition of respiratory symptoms, pulmonary function, and radiological investigations are indicated in selected symptomatic cases.

多巴胺激动剂治疗催乳素瘤患者肺纤维化:巧合或后果。
催乳素瘤是最常见的功能性垂体肿瘤,通常使用多巴胺激动剂如溴隐亭或卡麦角林治疗。尽管这些药物在降低催乳素水平和肿瘤大小方面通常具有良好的耐受性和有效性,但它们与罕见但严重的纤维化并发症(包括间质性肺疾病(ILD))有关。我们描述了一位65岁的患有长期催乳素瘤的男性,他接受了数十年累积大剂量溴隐亭和卡麦角林治疗。尽管最初肿瘤缩小,并通过多巴胺激动剂、立体定向放射手术和经蝶窦手术对高泌乳素血症进行了部分生化控制,但患者仍出现进行性用力呼吸困难和咳嗽,并伴有影像学和组织病理学表现,符合“常规间质性肺炎”(UIP)。自身免疫和环境原因在很大程度上被排除,提示药物诱导的病因。停用卡麦角林后,继续监测患者的催乳素水平和肿瘤状况,并对症治疗UIP。该病例强调了多巴胺激动剂相关ILD的可能性,即使在催乳素瘤患者中,通常每周接受的剂量低于帕金森病和相关疾病患者。早期识别呼吸系统症状,肺功能和放射检查是指在一些有症状的病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信